Asthma is a chronic inflammatory airway disease associated with type 2 cytokines
interleukin-4 (IL-4), IL-5, and IL-13, which promote airway eosinophilia, mucus …

“Treatable traits” have been proposed as a new paradigm for the management of airway
diseases, particularly complex disease, which aims to apply personalised medicine to each …

Rationale: Coronavirus disease (COVID-19) is caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2). ACE2 (angiotensin-converting enzyme 2), and …

Severe asthma imposes a significant burden on patients, families and healthcare systems.
Management is difficult, due to disease heterogeneity, co‐morbidities, complexity in care …

Rationale: Extracellular DNA (eDNA) and neutrophil extracellular traps (NETs) are
implicated in multiple inflammatory diseases. NETs mediate inflammasome activation and IL …

Evaluation and effective management of asthma, and in particular severe asthma, remains
at the core of pulmonary practice. Over the last 20–30 years, there has been increasing …

Rationale: Cross-sectional analysis of mucus plugs in computed tomography (CT) lung
scans in the Severe Asthma Research Program (SARP)-3 showed a high mucus plug …

Rationale: Cross-sectional studies suggest an exacerbation-prone asthma (EPA) phenotype
and the utility of blood eosinophils and plasma IL-6 as predictive biomarkers. Objectives: To …

Asthma is a disease of reversible airflow obstruction characterised clinically by wheezing,
shortness of breath, and coughing. Increases in airway type 2 cytokine activity, including …

Childhood asthma represents a heterogeneous challenging disease, in particular in its
severe forms. The identification of different asthma phenotypes has stimulated research in …